Commercialization Analytics and Insights Manager

PharmaEssentia Australia operations: is it the best move yet? PharmaEssentia Australia operations are set to begin in October, with the company pursuing dual drug approvals for PV and ET. This strategic move could reshape their market presence. Overview of PharmaEssentia's expansion. PharmaEssentia has recently announced its plans to launch operations in Australia, marking a significant step in its global expansion strategy. This move comes as the company aims to pursue dual drug approvals for essential treatments in polycythemia vera (PV) and essential thrombocythemia (ET). With the Australian market presenting promising opportunities, PharmaEssentia's Australia operations are set to enhance patient access to innovative therapies. The decision to establish a presence in Australia is driven by several key factors: * Market Potential: Australia has a well-established healthcare system and a growing demand for advanced treatments. * Regulatory Environment: The country's regulatory framework is conducive to facilitating drug approvals, making it an attractive destination for pharmaceutical companies. * Collaboration Opportunities: Local partnerships can enhance research and development efforts, further accelerating the launch of life-saving medications. As PharmaEssentia embarks on this new chapter, stakeholders are eager to see how the company will navigate the complexities of the Australian market and what impact its operations will have on patients suffering from PV and ET. What Are PV and ET? PharmaEssentia Australia operations are set against the backdrop of two significant blood disorders: Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Polycythemia Vera is a type of blood cancer that causes the bone marrow to produce too many red blood cells. This overproduction can lead to serious complications, including blood clots, stroke, or heart attack. Patients often experience symptoms such as headaches, dizziness, and fatigue. On the other hand, Essential Thrombocythemia is characterized by an increase in platelets, which can also lead to clotting issues. Individuals with ET may face symptoms like headaches, vision changes, or even a feeling of fullness in the abdomen due to an enlarged spleen. Both conditions are part of the myeloproliferative neoplasms group and require careful management. PharmaEssentia's focus on obtaining dual drug approvals for PV and ET signifies its commitment to addressing these complex medical needs. The company's strategic move into Australia highlights its vision to improve treatment options for patients affected by these disorders. Timeline for Australia operations. PharmaEssentia's timeline for Australia operations has been meticulously planned, aligning with its strategic goals for expanding its footprint in the region. The company announced its intention to launch operations in October 2023, marking a significant milestone in its global expansion strategy. As part of this rollout, PharmaEssentia aims to pursue dual drug approvals for Polycythemia Vera (PV) and Essential Thrombocythemia (ET) within the Australian market. The timeline is structured as follows: * July 2023: Initial regulatory discussions began with the Therapeutic Goods Administration (TGA). * August 2023: Submission of clinical trial data to support drug approvals. * September 2023: Anticipated feedback from the TGA on submission status. * October 2023: Official launch of PharmaEssentia Australia operations. This timeline not only emphasizes PharmaEssentia's commitment to Australia operations but also highlights the urgency in addressing the medical needs associated with both PV and ET in the Australian population. Impact on the Pharmaceutical market. The launch of PharmaEssentia Australia operations is poised to significantly impact the pharmaceutical market, particularly in the realms of polycythemia vera (PV) and essential thrombocythemia (ET). This strategic move comes at a time when the demand for innovative treatments in these areas is on the rise. With PharmaEssentia's commitment to securing dual drug approvals for PV and ET, the company is expected to introduce new therapeutic options that could enhance patient outcomes. The following points highlight the potential implications of this expansion: * Increased Competition: The entry of PharmaEssentia into the Australian market may spur competition, prompting established companies to accelerate their research and development efforts. * Access to Treatments: Patients suffering from PV and ET may benefit from increased access to novel therapies, as PharmaEssentia aims to fill existing gaps in treatment options. * Investment Opportunities: The expansion could attract investments in the biotech sector, as stakeholders seek to capitalize on the anticipated growth of the Australian pharmaceutical landscape. Overall, PharmaEssentia Australia operations represents a significant shift that could reshuffle the dynamics of the pharmaceutical industry, benefiting both patients and investors alike. Regulatory challenges ahead. As PharmaEssentia Australia operations prepare to launch, the company faces significant regulatory challenges that could impact its success in the region. The Australian Therapeutic Goods Administration (TGA) has stringent guidelines that govern the approval of pharmaceuticals, which could complicate the process for the dual drug approvals for Polycythemia Vera (PV) and Essential Thrombocythemia (ET). Among the key hurdles are: * Clinical Trial Requirements: The TGA demands comprehensive data from clinical trials that demonstrate the safety and efficacy of the drugs before they can be considered for approval. * Compliance with Local Regulations: PharmaEssentia must navigate the complex regulatory landscape that includes not only TGA requirements but also state-specific laws. * Market Access Strategies: Gaining reimbursement approvals from the Pharmaceutical Benefits Scheme (PBS) will be essential for ensuring that patients can access the new therapies. PharmaEssentia's ability to effectively address these regulatory challenges will play a crucial role in determining whether their operations in Australia become a landmark success or face significant setbacks. Future prospects for PharmaEssentia. The future prospects for PharmaEssentia Australia operations appear promising, as the company embarks on a strategic path to secure dual drug approvals for Polycythemia Vera (PV) and Essential Thrombocythemia (ET). This move not only positions PharmaEssentia to capture a significant share of the Australian market but also enhances its global footprint in the pharmaceutical industry. Industry analysts predict that the successful launch could lead to a surge in demand for their innovative treatments, catering to a patient demographic that has long awaited effective therapies. Moreover, as awareness of rare blood disorders grows, PharmaEssentia is likely to benefit from increased visibility and support from healthcare providers. However, the company must navigate various regulatory hurdles and ensure compliance with Australian health standards. The ability to adapt to the unique market dynamics will be crucial for sustained success. In addition, forging partnerships with local healthcare institutions may provide valuable insights and facilitate smoother operations. In summary, if executed effectively, PharmaEssentia Australia operations could signify a major step forward for the company and improve treatment options for patients suffering from PV and ET. Conclusion: what this means for patients. As PharmaEssentia Australia operations prepare to launch, the implications for patients suffering from Polycythemia Vera (PV) and Essential Thrombocythemia (ET) are significant. The company's entry into the Australian market aims to provide new treatment options and improve access to essential therapies. The anticipated dual drug approvals for PV and ET could lead to a transformative impact on patient care. With increased availability of these treatments, patients may experience improved management of their conditions, reducing the burden of symptoms and enhancing their quality of life. Moreover, the expansion signifies a commitment to addressing the medical needs of Australians affected by these rare blood disorders. As PharmaEssentia positions itself within the market, healthcare professionals will have more tools at their disposal, potentially leading to better patient outcomes. However, challenges remain, including navigating regulatory hurdles and ensuring that healthcare providers are adequately informed about the new therapies. The success of PharmaEssentia Australia operations will ultimately be measured by how well it meets the needs of patients and integrates into the existing healthcare framework. * Improved access to treatments for PV and ET * Potential for enhanced patient outcomes * Commitment to addressing rare blood disorders Many industry experts believe that the recent changes in PharmaEssentia Australia operations could lead to significant advancements in local drug production. As the market continues to evolve, the effectiveness of PharmaEssentia Australia operations will be closely monitored by stakeholders and analysts alike.

PharmaEssentia to present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting. Presentations highlight two-year Phase 3 data and real-world evidence for BESREMi(R)(ropeginterferon alfa-2b) in essential thrombocythemia (ET) BESREMi was recently FDA-approved for the treatment of adults with ET, regardless of genotype or disease status BURLINGTON, Mass, September 9, 2026 - PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced two poster presentations at the 2026 Society of Hematologic Oncology (SOHO) Annual Meeting, which will be held September 9-12 in Houston, Texas. PharmaEssentia will present two-year results from the Phase 3 SURPASS-ET study (NCT04285086) and its ongoing extension in adults with high-risk essential thrombocythemia (ET) who were resistant to or intolerant of hydroxyurea. In the extension, it was observed that study participants who continued BESREMi(R)(ropeginterferon alfa-2b-njft) maintained modified ELN response rates and platelet and white blood cell control through two years, with continued reduction in JAK2V617F variant allele burden and a safety profile consistent with prior reports. Patients followed in the extension study who transitioned from anagrelide to BESREMi after the 52-week core study showed improved hematologic control and reduced JAK2V617F allele burden relative to their prior anagrelide therapy. Long-term efficacy and safety analyses are ongoing. Two-year results were presented in part as an oral presentation at the European Hematology Association (EHA) 2026 Congress. Additionally, PharmaEssentia will present real-world evidence from a retrospective cohort study of 55 patients with ET evaluating the use of BESREMi in community oncology settings. The analysis found that BESREMi was most commonly initiated after first-line therapy, while first-line use was also observed, predominantly in younger patients. Platelet counts and response rates trended toward optimal levels regardless of prior cytoreductive therapy history. Poster Presentation Details Title: Efficacy and Molecular Dynamics of Ropeginterferon Alfa-2b in High-risk Essential Thrombocythemia: Two-year Results from the Phase 3 SURPASS-ET Trial Abstract Number: 944 Poster Number: MPN-944 Presenter: Dr. Lucia Masarova, University of Texas MD Anderson Cancer Center Date: 9/9/26 Time: 6:25-7:55 PM Title: Real-world Patient Characteristics, Treatment Patterns and Blood Counts of Patients with Essential Thrombocythemia Treated with Ropeginterferon Alfa-2b in the US Community Oncology Setting Abstract Number: 1090 Poster Number: MPN-1090 Presenter: Dr. Solly Chedid, Singing River Cancer Center Date: 9/9/26 Time: 6:25-7:55 PM About PharmaEssentia PharmaEssentia USA Corporation, located in Burlington, Massachusetts, is a subsidiary of PharmaEssentia Corporation (TWSE: 6446). PharmaEssentia Corporation, headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. For more information about PharmaEssentia USA, visit the website, LinkedIn or X (formerly Twitter). About Essential Thrombocythemia (ET) Essential thrombocythemia (ET) is a rare blood disorder and type of myeloproliferative neoplasm (MPN). It is characterized by the bone marrow overproducing platelets. Patients with ET are at an increased risk of blood clots, abnormal bleeding and enlarged spleens. ET is often caused by genetic mutations such as a JAK2 genetic mutation. About BESREMi(R)(ropeginterferon alfa-2b-njft) Ropeginterferon alfa-2b-njft is currently FDA-approved and marketed as BESREMi(R) for the treatment of adults with polycythemia vera (PV) and essential thrombocythemia (ET). BESREMi(R) holds orphan drug designation in the United States for the treatment of polycythemia vera and essential thrombocythemia in adults. The product was developed by PharmaEssentia. PharmaEssentia retains full global intellectual property rights across all indications. INDICATION BESREMi(R) is indicated for the treatment of adults with polycythemia vera and for the treatment of adults with essential thrombocythemia. IMPORTANT SAFETY INFORMATION WARNING: RISK OF SERIOUS DISORDERS Interferon alfa products may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and withdraw therapy with persistently severe or worsening signs or symptoms of the above disorders. CONTRAINDICATIONS * Existence of, or history of severe psychiatric disorders, particularly severe depression, suicidal ideation or suicide attempt * Hypersensitivity to interferons or to any of the inactive ingredients in BESREMi * Hepatic impairment (Child-Pugh B or C) * History or presence of active serious or untreated autoimmune disease * Immunosuppressed transplant recipients WARNINGS AND PRECAUTIONS * Depression and Suicide: Monitor for symptoms and need for treatment. * Endocrine Toxicity: Discontinue if endocrine disorders occur that cannot be medically managed. * Cardiovascular Toxicity: Avoid use in patients with severe or unstable cardiovascular disease. Monitor patients with history of cardiovascular disorders more frequently. * Hematologic and Hemorrhagic Disorders: Perform blood counts at baseline, every 2 weeks during titration, and at least every 3-6 months during maintenance treatment. * Hypersensitivity Reactions: Stop treatment and immediately manage reaction. * Pancreatitis: Consider discontinuation if confirmed pancreatitis. * Colitis: Discontinue if signs or symptoms of colitis. * Pulmonary Toxicity: Discontinue if pulmonary infiltrates or pulmonary function impairment. * Ophthalmologic Toxicity: Monitor for ocular toxicity. Promptly evaluate eye symptoms and discontinue if new or worsening eye disorders. * Hyperlipidemia: Monitor serum triglycerides before BESREMi treatment and intermittently during therapy and manage when elevated. * Hepatotoxicity: Monitor liver enzymes and hepatic function at baseline and during treatment. Reduce dose or discontinue depending on severity. * Renal Toxicity: Monitor serum creatinine at baseline and during therapy. Discontinue if severe renal impairment develops. * Dental and Periodontal Toxicity: Advise on good oral hygiene and regular dental examinations. * Dermatologic Toxicity: Consider discontinuing if clinically significant dermatologic toxicity. * Driving and Operating Machinery: Advise patients to avoid driving or using machinery if they experience dizziness, somnolence, or hallucination. * Embryo-Fetal Toxicity: Can cause fetal harm. Contacts. Media Muriel Huang Director, Investor Relations and Corporate Communications [email protected]